AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02528890 — intervention group
Intervention type: OTHER
Intervention: vaginal/anal swab for GBS from all participants
Description: All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
Study NCT00689559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: AZD3480 capsules qd, oral, 22 days
Study NCT00689559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo qd, 12 days
Study NCT00689559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: single dose on day 5
Study NCT00621595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: USDA School Breakfast
Description: Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
Study NCT01131065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin
Description: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
Study NCT00478114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib in the patients with advanced Renal Cell Carcinoma
Study NCT03441607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mHACMb
Description: Active ingredient
Study NCT03441607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive ingredient
Study NCT02123836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: 7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter.
Study NCT06153186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine Hydrochloride
Description: Flunarizine tablet
Study NCT03796442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVR with AVALUS
Description: aortic valve replacement with AVALUS bioprosthesis
Study NCT03796442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVR with CEPME
Description: aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
Study NCT00131365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Study NCT01258179 — intervention group
Intervention type: OTHER
Intervention: Analysis of PSP and PAP from venous blood samples
Description: to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
Study NCT00732758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000 IU
Description: Vitamin D3 1000 IU Tablet once daily for 6 months
Study NCT00732758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Tablet once daily for 6 months
Study NCT04376086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Segmental epidural analgesia
Study NCT04376086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia
Study NCT02757937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health & Wellness Website
Description: Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
Study NCT02757937 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Description: Continue with standard diabetes care without getting access to the intervention website.
Study NCT03653377 — intervention group
Intervention type: OTHER
Intervention: Self administrated questionnaire
Description: Questionnaires are distributed to patients with their parents during their visit to the CF center.
Study NCT02216149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
Study NCT02216149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
Study NCT02216149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 D1 every 3 weeks
Study NCT02216149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 D1 every 3 weeks
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine HCL matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine HCL matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pseudoephedrine matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT02892513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous auricular neurostimulation
Description: The Bridge device (manufactured by Key Electronics \[Jeffersonville, IN, USA\] and distributed by Innovative Health Solutions \[Versailles, IN, USA\]) provides continual neurostimulation for five days with alternating current.
Study NCT02892513 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham percutaneous auricular neurostimulation
Description: Identical in appearance to active, device, but no stimulation will be given.
Study NCT00456508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: solution for SC injection, one 30 mg dose per HAE attack
Study NCT03540303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR19 T cells carrying cytoplasmic activated PD-1
Description: step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Study NCT02958358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT imaging, functional PET imaging
Description: Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
Study NCT02211963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847
Study NCT02211963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02474589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tecovirimat
Description: Study is based on Animal Regulatory Rule
Study NCT02474589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Does not apply
Study NCT03906292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg QD and asciminib 60 mg QD
Study NCT03906292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Description: Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
Study NCT03906292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg QD and asciminib 80 mg QD
Study NCT03906292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD Monotherapy
Study NCT04169672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.
Study NCT04169672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT00798174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard configuration vs. azygos coil
Description: Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
Study NCT01395043 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placing bilateral TAP-catheters preoperatively
Description: Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
Study NCT01395043 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters
Description: Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
Study NCT02341144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-op percutaneous rectus sheath block
Description: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Study NCT02341144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative rectus sheath block
Description: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Study NCT02341144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT01073839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and Gemcitabine
Description: Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
Study NCT02137538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02137538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Study NCT00432835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Description: All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
Study NCT00883103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine jelly
Description: 2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Study NCT00883103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plain aqueous gel
Description: Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Study NCT02435771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 1- 400,000 IU
Study NCT02435771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 2- 800,000 IU
Study NCT02304250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 1ml (5mg)
Study NCT02304250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 1ml
Study NCT01158430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT group therapy
Description: Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours
Study NCT01677780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
Study NCT00975572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 30 μg
Description: 440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
Study NCT00975572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg
Description: 440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
Study NCT00975572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
Description: 440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
Study NCT00975572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg
Description: 330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
Study NCT00975572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
Study NCT00975572 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo control
Description: 110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
Study NCT04532021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements
Description: These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
Study NCT02941393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine pressure catheter
Study NCT02941393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External tocodynamometry
Study NCT01432535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN-2b (Sylatron®)
Description: Single 4.5 μg/kg dose
Study NCT01432535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-2b (Sylatron®)
Description: Single 4.5 μg/kg dose
Study NCT00313911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T
Description: 0.5 mL, Intramuscular (IM)
Study NCT03714854 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
Study NCT03714854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
Study NCT00313911 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib
Description: 0.5 mL, Intramuscular
Study NCT00636792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
Study NCT00636792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
Study NCT00636792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
Study NCT04107623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
Study NCT01574430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: 30% or 50% verteporfin dose PDT was given to patients with CSC
Study NCT01574430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: 30% or 50% verteporfin dose PDT was given to patients with CSC
Study NCT03009890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (Open Reduction Internal Fixation)
Description: Either volar of dorsal plating or both
Study NCT03009890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast treatment
Description: Hospitals may use their preferred protocol
Study NCT00818415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium ER (BAYH6689)
Description: Extented release Naproxen sodium (660mg) administered once a day
Study NCT00818415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Naproxen (Aleve, BAYH6689)
Description: Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
Study NCT04367402 — intervention group
Intervention type: OTHER
Intervention: BioMedomics COVID-19 IgM-IgG Rapid Test
Description: Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
Study NCT01231685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
Study NCT01231685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
Study NCT01231685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor
Description: Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Study NCT01231685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor
Description: Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Study NCT00847392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound prior to bladder catheterization
Description: Bedside ultrasound to estimated volume of urine in bladder
Study NCT00835679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00835679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT00835679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00835679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04512599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic Bar
Description: The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.